chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Prolonged crying; no fever; no other sx; not consolable; lasted about 6 hrs;
BODY ACHES; TIREDNESS; This spontaneous report received from a consumer concerned a 78 year old male. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805020 expiry: UNKNOWN) dose was not reported, administered on 12-MAR-2021 for prophylactic vaccination. The batch number was not reported. The company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On 14-MAR-2021, the subject experienced body aches. On 14-MAR-2021, the subject experienced tiredness. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from body aches, and tiredness on MAR-2021. This report was non-serious. This case, from the same reporter is linked to 20210355363.
Warm; Itchy; Chills; Around the injection site, it is swollen; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (Warm), VACCINATION SITE PRURITUS (Itchy), CHILLS (Chills) and VACCINATION SITE SWELLING (Around the injection site, it is swollen) in an 88-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 014M204) for COVID-19 vaccination.     No Medical History information was reported.   On 07-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 08-Mar-2021, the patient experienced VACCINATION SITE WARMTH (Warm), VACCINATION SITE PRURITUS (Itchy), CHILLS (Chills) and VACCINATION SITE SWELLING (Around the injection site, it is swollen). At the time of the report, VACCINATION SITE WARMTH (Warm), VACCINATION SITE PRURITUS (Itchy), CHILLS (Chills) and VACCINATION SITE SWELLING (Around the injection site, it is swollen) outcome was unknown.            Action taken with mRNA-1273 in response to the event was not applicable. Treatment details included Cocoa butter and shea butter.
High blood pressure problems; This spontaneous case was reported by a consumer and describes the occurrence of HYPERTENSION (High blood pressure problems) in a 68-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 044H21H and 011A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 24-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced HYPERTENSION (High blood pressure problems). At the time of the report, HYPERTENSION (High blood pressure problems) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications was reported.  No treatment drug details was reported.
The patients did not experience any symptoms; patient was vaccinated with improperly stored varivax; This spontaneous report as received from a medical assistant refers to a 12 months old female patient. The patient's pertinent medical history and drug reactions or allergies were not reported. The patient's concomitant therapy included sterile diluent. On 03-FEB-2020, the patient was vaccinated with improperly stored varicella virus vaccine live (oka/merck)(VARIVAX) for prophylaxis (strength, dose, route of administration and anatomical location were not reported) of lot # S006647 is an invalid lot number, expiry date reported as 05-MAR-2021 for prophylaxis (product storage error). The patient did not experience any symptoms. The outcome of product storage error was unknown. The temperature excursion for varicella virus vaccine live (oka/merck) (VARIVAX) was reported as -9 degrees Celsius (C) to 8 degrees Celsius (3.3 C) for 53 hours. There was no previous temperature excursion reported. Data logger was involved. No product quality complaint (PQC) was associated with this report.  This is one of the multiple reports from the same reporter.; Sender's Comments:  US-009507513-1911USA011629:
Patient has not eaten today. She felt light headed with vaccine . Offered juice, crackers, water. Kept for observation, till 9:00  AM Pulse 48 SPO2 99% BP 98/50 Discharge home as she get normal.
Lg oval shape red warm hard area on upper LT arm. Parents used ice packs Tuesday night with some relieve.
Numb left side of torso, whole neck, left side of face for two days. Left eye twitching for 3 days. Left side weak so could pick up dog for 5 days. Weakness and some numbness continues up time of report.
couple of symptoms; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (couple of symptoms) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (couple of symptoms). At the time of the report, VACCINATION COMPLICATION (couple of symptoms) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medication information was not provided by the reporter.  Treatment information was not provided by the reporter.
10 min after it felt like blood pressure dropped, quickly and sharp like if I had dropped from a tall building, then quick pulses, and then I felt my lungs were full/heavy.
Swelling of (L) upper arm, hot to touch, pain with shoulder movement evening of vaccine administration. Following day "very swollen" with ROM although some improvement from NOC before. No fluctuance or drainage.
second dose 2 weeks after first; This spontaneous case was reported by an other health care professional and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (second dose 2 weeks after first) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027C21D) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (second dose 2 weeks after first). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (second dose 2 weeks after first) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was mentioned.  No treatment medication was mentioned.
The night after the hepatitis a vaccine I noticed my legs were tingling and felt very weird while I was trying to go to sleep.  I went to sleep and got up the next day and went to work.  My legs still felt very odd and weak.  Over the next few days and weeks I experienced tingling, burning pain in my legs and arms.  Around week 4 I noticed it felt hard to breathe.  I would not be able to fall asleep at night because it felt like if I wasn't awake to think to breathe I would stop breathing.  My heart would also feel like it was fluttering or beating weird.  I went to several doctors through out these 10 weeks because none seemed to take me seriously or really be knowledgeable about what this could be.  I was so weak and didn't have energy to do much.  I had to stop working and only worked one hour every 30 days in order to keep my job.  It was all I could do to go to school and come home.  I have always enjoyed exercise and still have not exercised in over 10 weeks now.  Between weeks 3-6 it got very hard to walk.  I would notice myself using my hands to stand up out of a chair.  I also had bad headaches during this time.  I literally felt weird, tingling sensations in my head.  It has now been over 10 weeks, and I still have nerve pain (burning, tingling), especially in my legs and butt area.  I get tired very easily and feel weak still but am doing much better than I have been.  I will get sharp pains in my shoulders or arms and legs occasionally too.
R arm Shingrix shot. L arm Tetanus/whooping cough shot. R arm almost immediately felt bruised, very uncomfortable. Within 90 minutes Pt felt malaise, body chills, headache, fever, weakness, achy, R leg cramping, and decrease in appetite. R side body affected more the the left. Pt took Tylenol / 1 Tylenol 500 mg on 11/23/2020. Pt hydrating, still achy, limited energy almost 24 hours later.   Pending lab work part of routine physical same day.   Had flu shot October 2, 2020. Taking amoxacillan at this time due to tooth extraction.
Macular, papular, erythematous, rash to trunk, and extremities.
Following vaccination, patient experienced syncope episode and fell to floor. He regained consciousness very quickly but felt dizzy and nauseous for a little longer. Observed patient and he was feeling better prior to leaving pharmacy.
Received first dose of covid vaccine at 7pm, woke up the next morning with a severe, throbbing headache, chills, and body aches which lasted all day.; Received first dose of covid vaccine at 7pm, woke up the next morning with a severe, throbbing headache, chills, and body aches which lasted all day.; Received first dose of covid vaccine at 7pm, woke up the next morning with a severe, throbbing headache, chills, and body aches which lasted all day.; This is a spontaneous report from a contactable nurse, the patient. A 44-years-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, solution for injection, lot number: EN6201), via an unspecified route of administration on 09Feb2021 19:15 as dose 1, single (at the age of 44-years-old) for covid-19 immunization. The patient medical history and concomitant medications were not reported. After the first dose of covid vaccine at 7pm, the patient woke up the next morning on 10Feb2021 with a severe, throbbing headache, chills, and body aches which lasted all day. Therapeutic measures were not taken for the reported events. The patient did not receive any other vaccine in four weeks. The outcome of the events was recovering.  Follow-up attempts completed. No further information expected.
Systemic: Dizziness / Lightheadness-Medium, Systemic: Hyperventilation-Mild, Systemic: Tachycardia-Medium, Systemic: Weakness-Medium, Additional Details: Patient started feeling dizzy 5 minutes after the vaccine administration. Upon checking her heart rate was in the range of 105-135 bpm. 10 minutes later paramedics came and checked patient's blood glucose, blood pressure and EKG and everything came normal. Patient said she will follow up with a doctor regarding this and went home.
pt recv vax&devel a mild case of chickenpox;no further details were provided;
No adverse effect was noted during the visit. The intake personnel at the covid vaccination clinic report that the family led them to believe that they were here for their daughters 2nd dose in the series. After the vaccine administration the nurse verbally asked "this was the 2nd dose, correct?" and at that time was told by the family that this was a booster dose. The family went on to say that they were instructed by their pediatrician that they needed to get their daughters a booster due to traveling frequently.
My wife also received both doses of the vaccine and she has a rash between her fingers and itching at the top of her hand.; My wife also received both doses of the vaccine and she has a rash between her fingers and itching at the top of her hand.; This is a spontaneous report from a contactable consumer. This consumer reported for his wife. A 38-year-old female patient received BNT162B2 (Pfizer Covid 19 vaccine Formulation: Solution for injection Batch/Lot number: Unknown Expiration Date: Unknown) via an unspecified route of administration on an unspecified date as DOSE 1, SINGLE and received BNT162B2 (Pfizer COVID-19 vaccine Formulation: Solution for injection Batch/Lot number: Unknown Expiration Date: Unknown) via an unspecified route of administration on an unspecified date as DOSE 2, SINGLE for COVID-19 immunization. The patient medical history and concomitant medications were not reported. The patient received both doses of the vaccine and she has a rash between her fingers and itching at the top of her hand. on an unspecified date. Outcome of both events was unknown.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Case number PHEH2013US019142 is an initial spontaneous report from the medical assistant received on 11 Sep 2013 with a follow-up received on 03 Oct 2013. This report refers to a 17-year-old female patient. Her vaccination status was up to date and she was healthy. On 09 Sep 2013, the patient was accidentally administered with Men A powder vial of MENVEO (batch number: M12130) mixed with a sterile diluent of MMR. The solution was injected intramuscularly in to the left arm. The reporter wanted to confirm whether to wait for certain time to again administer the correct dose of MENVEO or it can be administered. The nurse stated that the patient would be vaccinated with the correctly re-constituted vaccine. No adverse event reported following this medication error. Follow-up received from the nurse on 03 Oct 2013: Updated patient demographics, batch number of MENVEO, confirmation on the diluent used from MMR vaccine and information about re-vaccination.
parosmia; anosmia; This spontaneous case was reported by a physician and describes the occurrence of PAROSMIA (parosmia) and ANOSMIA (anosmia) in a 52-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026A21A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 09-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-Mar-2021, the patient experienced PAROSMIA (parosmia) and ANOSMIA (anosmia). At the time of the report, PAROSMIA (parosmia) and ANOSMIA (anosmia) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. It was reported that a patient who within a minute after getting the 1st dose of vaccine has experienced events. No treatment medications were reported.  Company comment: This spontaneous case reported by a physician concerns a 52-year-old male patient with no reported medical history, who experienced the non- serious unexpected events of Anosmia (AESI) and Parosmia which occurred on the same day (within 1 minute) after administration of first dose of mRNA-1273 vaccine. Events were ongoing at the time of the report. Rest of the details are not available for medical review. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.    Reporter did not allow further contact
This case was reported by a consumer and described the occurrence of spasms in a 50-year-old male patient who received DTPa vaccine. Co-suspect products included Hepatitis B vaccine, Meningococcal vaccine, Poliovirus vaccine, Yellow Fever, Typhoid, MALARONE tablet for malaria prophylaxis and CIPRO unknown for an unknown indication. The patient's past medical history included hypertension. Concurrent medical conditions included arthritis. Concomitant products included hydrochlorothiazide (HCTZ). On 8th July 2009, the patient received DTPa vaccine. On 2nd July 2009, the patient received Hepatitis B vaccine, Meningococcal vaccine and Poliovirus vaccine. On 8th July 2009, the patient started Yellow Fever at an unknown dose and frequency. On 2nd July 2009, the patient started Typhoid at an unknown dose and frequency. On 28th August 2009, the patient started MALARONE (oral) 1 tablet once daily (1 tablet daily). On an unknown date, the patient started CIPRO at an unknown dose and frequency. On 30th August 2009, 53 days after receiving DTPa vaccine, 59 days after receiving Hepatitis B vaccine and 2 days after starting MALARONE and CIPRO, the patient experienced spasms, back pain and insomnia. The action taken with MALARONE was discontinued (Dechallenge was positive). Rechallenge with MALARONE was negative. On an unknown date, the outcome of the spasms, back pain and insomnia were recovering/resolving. It was unknown if the reporter considered the spasms, back pain and insomnia to be related to DTPa vaccine, Hepatitis B vaccine, MALARONE and CIPRO. A male patient who was 50 years of age at time of event. reports back pain and back spasms while taking MALARONE. The patient described these symptoms as wave-like. He also had trouble sleeping due to the back pain. The onset of symptoms began two days into therapy. The patient was seen by a physician who ordered the MALARONE to be discontinued. Total days on therapy were five days. The symptoms began to improve 2 days after discontinuation. The patient did report that he has some back pain to date, but he attributes this to arthritis. The dosing of MALARONE was the started dosing strength. CIPRO was given with the MALARONE as a precautionary prophylaxis for going to teach in another country. I asked if he is relating his current back pain to MALARONE and he said no.
diagnosed with COVID-19; This case was reported by a consumer via call center representative and described the occurrence of covid-19 in a male patient who received Flu Seasonal QIV Dresden (Influenza vaccine Quadrivalent 2020-2021 season) for prophylaxis.   On an unknown date, the patient received Influenza vaccine Quadrivalent 2020-2021 season. On an unknown date, less than a week after receiving Influenza vaccine Quadrivalent 2020-2021 season, the patient experienced covid-19. On an unknown date, the outcome of the covid-19 was unknown.   It was unknown if the reporter considered the covid-19 to be related to Influenza vaccine Quadrivalent 2020-2021 season.  Additional details were provided as follows: The age at vaccination was not reported. The patient received Influenza vaccine Quadrivalent 2020-2021 season and experienced covid 19 which was recovered . The patient was not sure about the name of the the vaccine if it was Fluarix or Flulaval, but his HCP told him it was manufactured by GSK. The patient stated that he had the flu vaccine 3 weeks back and about 2 weeks back he was diagnosed with COVID 19. The reporter consented to follow up. No further information was available. This case was linked with case US2020221384.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020221384:same reporter
Administration of an invalid dose (storage and use on pediatrics); Inappropriate age at vaccine administration; This spontaneous case was reported by a nurse and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Administration of an invalid dose (storage and use on pediatrics)) and PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Inappropriate age at vaccine administration) in a 17-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013M21A) for COVID-19 vaccination.     Concurrent medical conditions included No adverse event (No reported medical history).    On 22-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Mar-2021, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Administration of an invalid dose (storage and use on pediatrics)) and PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Inappropriate age at vaccine administration). On 22-Mar-2021, POOR QUALITY PRODUCT ADMINISTERED (Administration of an invalid dose (storage and use on pediatrics)) and PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Inappropriate age at vaccine administration) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter. No treatment information was provided.   This case was linked to MOD-2021-056335 (Patient Link).
Patient is a 69-year-old female. She presents emergency room today for anaphylaxis. She states that she has had a reaction similar to this previously when she took penicillin and vancomycin. She states that she felt like she had to clear her throat a lot over the last 24 hours. She also noticed a diffuse red raised rash that was itchy as well. She noted that this started out just like her previous anaphylaxis episodes and she presented to the emergency room for further evaluation.  In the emergency room she did receive multiple duo nebs, Solu-Medrol 125 mg, Pepcid, Benadryl. She did receive 0.3 epi and then again 0.5 of epi. She states that a week ago she did begin Carafate twice daily secondary to GERD. And she had contrast yesterday as she had an MRI performed.  She states that she has had contrast in the past and has had no reaction at that time. She did have her Moderna vaccine yesterday. She had previously had to Pfizer vaccines for Covid. She denies fever, chills, chest pain, abd pain, urinary symptoms, change in bowel habit.
This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (A sore left injection site arm.) in an 80-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. o23M20A) for COVID-19 vaccination. No Medical History information was reported. On 26-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to at an unspecified dose. On 25-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to at an unspecified dose. On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) at an unspecified dose. On an unknown date, the patient experienced PAIN IN EXTREMITY (A sore left injection site arm.). At the time of the report, PAIN IN EXTREMITY (A sore left injection site arm.) outcome was unknown. Not Provided. DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: negative (Negative) negative. No concomitant and treatment medications were given. No patient past history were provided. Most recent FOLLOW-UP information incorporated above includes: On 03-Sep-2021: Folow up received on 03-SEP-2021 lab data has been updated.